- Home
- COCH vs ACRV Comparison
COCH vs ACRV Comparison
Compare COCH & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COCH
- ACRV
- Stock Information
- Founded
- COCH 1995
- ACRV 2018
- Country
- COCH United States
- ACRV United States
- Employees
- COCH N/A
- ACRV N/A
- Industry
- COCH Blank Checks
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- COCH Finance
- ACRV Health Care
- Exchange
- COCH Nasdaq
- ACRV Nasdaq
- Market Cap
- COCH 31.6M
- ACRV 34.5M
- IPO Year
- COCH N/A
- ACRV 2022
- Fundamental
- Price
- COCH $1.53
- ACRV $1.35
- Analyst Decision
- COCH Strong Buy
- ACRV Buy
- Analyst Count
- COCH 2
- ACRV 7
- Target Price
- COCH $9.25
- ACRV $17.60
- AVG Volume (30 Days)
- COCH 30.5K
- ACRV 758.0K
- Earning Date
- COCH 05-01-2025
- ACRV 05-14-2025
- Dividend Yield
- COCH N/A
- ACRV N/A
- EPS Growth
- COCH N/A
- ACRV N/A
- EPS
- COCH N/A
- ACRV N/A
- Revenue
- COCH $212,000.00
- ACRV N/A
- Revenue This Year
- COCH $8.04
- ACRV N/A
- Revenue Next Year
- COCH $15.39
- ACRV N/A
- P/E Ratio
- COCH N/A
- ACRV N/A
- Revenue Growth
- COCH N/A
- ACRV N/A
- 52 Week Low
- COCH $1.21
- ACRV $1.05
- 52 Week High
- COCH $3.99
- ACRV $10.16
- Technical
- Relative Strength Index (RSI)
- COCH 49.57
- ACRV 50.04
- Support Level
- COCH $1.39
- ACRV $1.06
- Resistance Level
- COCH $1.70
- ACRV $1.19
- Average True Range (ATR)
- COCH 0.13
- ACRV 0.09
- MACD
- COCH -0.03
- ACRV 0.07
- Stochastic Oscillator
- COCH 33.92
- ACRV 93.75
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life. The Company has one reportable segment: hearing. The hearing segment derives revenue from the sale of the Esteem FI-AMEI implants and replacement components to Esteem FI-AMEI implants.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.